In vivo, in an orthotopic GBM xenograft model, the combination of oAd-IL7 and B7H3-CAR-T resulted in a significant proportion of long-term survivors (i.e., 80%), while the monotherapy using either oAd-IL7 or B7H3-CAR-T alone did not yield any survivors. This evidence concerns the gene CD276 and glioblastoma.